Exploring the Anticancer Activity of Functionalized Isoindigos: Synthesis, Drug‐like Potential, Mode of Action and Effect on Tumor‐Induced Xenografts
Authors:
- 13 March 2012
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 7 (5) , 777-791
Abstract
Meisoindigo has been used as an indirubin substitute for the treatment of chronic myeloid leukemia (CML) for several years. In view of its poor solubility and erratic absorption, several investigations have focused on developing analogues with more desirable physicochemical profiles. Here, we investigated the structure–activity relationship (SAR) of meisoindigo with respect to its antiproliferative activity on leukemic K562 cells and found that appending a phenalkyl side chain onto the lactam NH resulted in analogues that retained good activity. Furthermore, analogues in which the phenyl ring was substituted with a basic heterocycle were significantly more soluble than meisoindigo while retaining acceptable antiproliferative profiles. The most promising analogue (E)‐1‐(2‐(4‐methylpiperazin‐1‐yl)ethyl)‐[3,3′‐biindolinylidene]‐2,2′‐dione (5‐4) is more potent than meisoindigo across a panel of malignant cells, with at least 40 times greater solubility than meisoindigo, little or no tendency to aggregate in solution and capable of significantly extending the lifespans of animals with K562 induced xenografts. Mechanistically, it induced apoptotic cell death and disrupted the progression of K562 cells from the G1 to G2 phase. Taken together, our findings highlighted the feasibility of addressing the physicochemical deficits of the isoindigo scaffold by systematic modifications which was achieved without overt loss of growth inhibitory activity.Keywords
This publication has 32 references indexed in Scilit:
- Synthesis and Bioactivity of Carbohydrate Derivatives of Indigo, Its Isomers and HeteroanaloguesChemMedChem, 2010
- Colloid Formation by Drugs in Simulated Intestinal FluidJournal of Medicinal Chemistry, 2010
- Meisoindigo is a promising agent within vitroandin vivoactivity against human acute myeloid leukemiaLeukemia & Lymphoma, 2010
- Synthesis and Biological Evaluation of 7‐Azaisoindigo DerivativesArchiv der Pharmazie, 2010
- Identification of circulatory and excretory metabolites of meisoindigo in rat plasma, urine and feces by high‐performance liquid chromatography coupled with positive electrospray ionization tandem mass spectrometryRapid Communications in Mass Spectrometry, 2010
- Stoichiometry and Physical Chemistry of Promiscuous Aggregate-Based InhibitorsJournal of the American Chemical Society, 2008
- An Integrated Computational Approach to the Phenomenon of Potent and Selective Inhibition of Aurora Kinases B and C by a Series of 7-Substituted IndirubinsJournal of Medicinal Chemistry, 2007
- Interpreting Steep Dose-Response Curves in Early Inhibitor DiscoveryJournal of Medicinal Chemistry, 2006
- Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrestOncogene, 2001
- Meisoindigo for the treatment of chronic myelogenous leukaemiaBritish Journal of Haematology, 2000